Jose Luis López-Campos 1 , 2 , María Abad Arranz 1 , Carmen Calero Acuña 1 , 2 , Fernando Romero Valero 3 , Ruth Ayerbe García 4 , Antonio Hidalgo Molina 3 , Ricardo I Aguilar Perez-Grovas 4 , Francisco García Gil 5 , Francisco Casas Maldonado 6 , Laura Caballero Ballesteros 5 , María Sánchez Palop 6 , Dolores Pérez-Tejero 7 , Alejandro Segado 7 , Jose Calvo Bonachera 8 , Bárbara Hernández Sierra 8 , Adolfo Doménech 9 , Macarena Arroyo Varela 9 , Francisco González Vargas 10 , Juan J Cruz Rueda 10
02 June 2016
This study is an analysis of a pilot COPD clinical audit that evaluated adherence to guidelines for patients with COPD in a stable disease phase during a routine visit in specialized secondary care outpatient clinics in order to identify the variables associated with the decision to step-up or step-down pharmacological treatment.
This study was a pilot clinical audit performed at hospital outpatient respiratory clinics in the region of Andalusia, Spain (eight provinces with over eight million inhabitants), in which 20% of centers in the area (catchment population 3,143,086 inhabitants) were invited to participate. Treatment changes were evaluated in terms of the number of prescribed medications and were classified as step-up, step-down, or no change. Three backward stepwise binominal multivariate logistic regression analyses were conducted to evaluate variables associated with stepping up, stepping down, and inhaled corticosteroids discontinuation.
The present analysis evaluated 565 clinical records (91%) of the complete audit. Of those records, 366 (64.8%) cases saw no change in pharmacological treatment, while 99 patients (17.5%) had an increase in the number of drugs, 55 (9.7%) had a decrease in the number of drugs, and 45 (8.0%) noted a change to other medication for a similar therapeutic scheme. Exacerbations were the main factor in stepping up treatment, as were the symptoms themselves. In contrast, rather than symptoms, doctors used forced expiratory volume in 1 second and previous treatment with long-term antibiotics or inhaled corticosteroids as the key determinants to stepping down treatment.